A recent meta-analysis of [18F]florzolotau-PET imaging in patients with PSP revealed the need for PET radiopharmaceuticals with higher selectivity for 4R-tau over 3R-tau and other CNS targets, including α-synuclein and Aβ, in order to detect disease-specific distribution of tau aggregates29. Here, MAPT is linked to supranuclear palsy, progressive, 1.